Prognostic Significance of Immunohistochemical Markers and Genetic Alterations in Malignant Peripheral Nerve Sheath Tumors: A Systematic Review.
clinicopathologic
genes
malignant peripheral nerve sheath tumors
markers
molecular
prognosis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
08
2020
accepted:
19
11
2020
entrez:
8
1
2021
pubmed:
9
1
2021
medline:
9
1
2021
Statut:
epublish
Résumé
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas with dismal prognosis. Pathological and genetic markers may predict more aggressive behavior in MPNSTs but have uncommonly been investigated, and few are used in daily practice. This study reviews the prognostic value of immunohistochemical markers and genetic alterations in MPNST. A systematic search was performed in PubMed and Embase databases according to the PRISMA guidelines. Search terms related to 'MPNST' and 'prognostic' were used. Studies investigating the association of immunohistochemical markers or genetic alterations with prognosis were included. Qualitative synthesis was performed on all studies. A distinction was made between univariable and multivariable associations. Forty-six studies were included after full-text screening. Sixty-seven different immunohistochemical markers were investigated. Absence of S100 and H3K27me3 and high Ki67 and p53 staining was most commonly independently associated with worse survival and disease-free survival. Several genetic alterations were investigated as well with varying association to survival. MPNSTs harbor complex and heterogeneous biology. Immunohistochemical markers and genetic alterations have variable prognostic value. Absence of S100 and H3K27me3 and increased Ki67 can be of prognostic value. Alterations in
Sections du résumé
BACKGROUND
BACKGROUND
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas with dismal prognosis. Pathological and genetic markers may predict more aggressive behavior in MPNSTs but have uncommonly been investigated, and few are used in daily practice. This study reviews the prognostic value of immunohistochemical markers and genetic alterations in MPNST.
METHODS
METHODS
A systematic search was performed in PubMed and Embase databases according to the PRISMA guidelines. Search terms related to 'MPNST' and 'prognostic' were used. Studies investigating the association of immunohistochemical markers or genetic alterations with prognosis were included. Qualitative synthesis was performed on all studies. A distinction was made between univariable and multivariable associations.
RESULTS
RESULTS
Forty-six studies were included after full-text screening. Sixty-seven different immunohistochemical markers were investigated. Absence of S100 and H3K27me3 and high Ki67 and p53 staining was most commonly independently associated with worse survival and disease-free survival. Several genetic alterations were investigated as well with varying association to survival.
CONCLUSIONS
CONCLUSIONS
MPNSTs harbor complex and heterogeneous biology. Immunohistochemical markers and genetic alterations have variable prognostic value. Absence of S100 and H3K27me3 and increased Ki67 can be of prognostic value. Alterations in
Identifiants
pubmed: 33415076
doi: 10.3389/fonc.2020.594069
pmc: PMC7783392
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
594069Informations de copyright
Copyright © 2020 Martin, Acem, Grünhagen, Bovée and Verhoef.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Hum Pathol. 2017 Sep;67:1-10
pubmed: 28551330
J Clin Oncol. 2010 Mar 20;28(9):1573-82
pubmed: 20159821
Oncotarget. 2018 May 1;9(33):23018-23028
pubmed: 29796169
Mol Cancer. 2008 Jun 03;7:48
pubmed: 18522746
Neuro Oncol. 2015 Jan;17(1):63-9
pubmed: 25038505
Clin Cancer Res. 2011 Apr 1;17(7):1924-34
pubmed: 21325289
Genes Chromosomes Cancer. 1994 Aug;10(4):250-5
pubmed: 7522538
Clin Cancer Res. 2011 Jun 1;17(11):3771-82
pubmed: 21262917
Lancet Oncol. 2017 Jun;18(6):812-822
pubmed: 28499583
Neurooncol Pract. 2019 Mar;6(2):134-143
pubmed: 31386019
Mod Pathol. 2016 Jan;29(1):4-13
pubmed: 26585554
Ann Surg. 2009 Jun;249(6):1014-22
pubmed: 19474676
Oncotarget. 2016 Apr 19;7(16):22234-44
pubmed: 26993773
Chin J Cancer. 2017 Oct 11;36(1):80
pubmed: 29020982
Cancer. 2006 Sep 1;107(5):1065-74
pubmed: 16881077
Ann Surg Oncol. 2012 Mar;19(3):878-85
pubmed: 21861229
Cancer Med. 2019 Mar;8(3):972-981
pubmed: 30735009
Clin Exp Metastasis. 2008;25(7):819-25
pubmed: 18679811
Histopathology. 2001 Aug;39(2):187-97
pubmed: 11493336
Am J Pathol. 1999 Dec;155(6):1885-91
pubmed: 10595919
Sarcoma. 2017;2017:8685638
pubmed: 29138631
Mod Pathol. 2017 Dec;30(12):1710-1719
pubmed: 28776579
PLoS One. 2014 Feb 06;9(2):e88035
pubmed: 24516579
Nature. 1992 Apr 23;356(6371):713-5
pubmed: 1570015
Eur J Cancer. 2016 Mar;56:77-84
pubmed: 26824706
Mod Pathol. 2018 Nov;31(11):1694-1707
pubmed: 29946184
Am J Surg Pathol. 2016 Jul;40(7):896-908
pubmed: 27158754
Ann Oncol. 2001 Jan;12(1):75-80
pubmed: 11249053
Clin Cancer Res. 2011 Jun 15;17(12):3943-55
pubmed: 21540237
Clin Transl Oncol. 2014 Feb;16(2):191-9
pubmed: 23749326
Oncotarget. 2017 Jul 4;8(62):104785-104795
pubmed: 29285213
Eur J Cancer. 2020 Jan;124:77-87
pubmed: 31760312
J Eur Acad Dermatol Venereol. 2013 Aug;27(8):1044-7
pubmed: 22348274
Cancer Genet Cytogenet. 1999 Aug;113(1):65-9
pubmed: 10459349
Neuro Oncol. 2008 Dec;10(6):946-57
pubmed: 18650488
Neoplasia. 2007 Aug;9(8):671-7
pubmed: 17786186
Cancer Biomark. 2019;24(3):351-361
pubmed: 30883338
Nature. 2014 Oct 9;514(7521):247-51
pubmed: 25119042
Mol Oncol. 2015 Jun;9(6):1129-39
pubmed: 25769404
Mod Pathol. 2016 Jun;29(6):582-90
pubmed: 26990975
Histopathology. 2017 May;70(6):946-953
pubmed: 27992966
BMC Genomics. 2013 Jul 13;14:473
pubmed: 23848554
Ann Surg Oncol. 2013 Jan;20(1):66-72
pubmed: 22878618
Sarcoma. 2008;2008:849156
pubmed: 18769552
PLoS One. 2017 May 30;12(5):e0178064
pubmed: 28558056
J Neurosurg. 2017 Jan;126(1):319-329
pubmed: 27035165
PLoS Comput Biol. 2019 Feb 20;15(2):e1006826
pubmed: 30785874
Nat Genet. 2014 Nov;46(11):1227-32
pubmed: 25240281
J Clin Oncol. 2003 Dec 15;21(24):4586-91
pubmed: 14673046
Neuro Oncol. 2009 Oct;11(5):514-28
pubmed: 19182148
J Neurooncol. 2009 Sep;94(3):383-8
pubmed: 19330289
Mod Pathol. 2006 Apr;19(4):524-32
pubmed: 16554732
Am J Clin Pathol. 1996 Sep;106(3):282-8
pubmed: 8816583
Genes Chromosomes Cancer. 2011 Dec;50(12):1021-32
pubmed: 21987445
J Dermatol Sci. 2016 Feb;81(2):118-23
pubmed: 26642794
Eur J Cancer. 1998 Mar;34(4):496-502
pubmed: 9713299
Neuro Oncol. 2013 Feb;15(2):135-47
pubmed: 23161774
Crit Rev Oncol Hematol. 2019 Jun;138:223-232
pubmed: 31092379
J Clin Oncol. 2005 Nov 20;23(33):8422-30
pubmed: 16293873
Arch Dermatol. 2001 Jul;137(7):908-13
pubmed: 11453810
Pediatr Blood Cancer. 2019 Oct;66(10):e27833
pubmed: 31241238
Am J Surg Pathol. 1992 Jul;16(7):694-707
pubmed: 1530109
Clin Cancer Res. 2012 May 1;18(9):2545-57
pubmed: 22407831
Pathol Res Pract. 2018 Mar;214(3):417-425
pubmed: 29482987
Clin Exp Metastasis. 2014 Aug;31(6):715-25
pubmed: 24957185
Pediatr Blood Cancer. 2020 Apr;67(4):e28138
pubmed: 31889416
Turk Neurosurg. 2018;28(6):983-988
pubmed: 29634079
Radiother Oncol. 2019 Aug;137:61-70
pubmed: 31078939
PLoS One. 2013 Nov 26;8(11):e80456
pubmed: 24303016
J Neurooncol. 2015 Apr;122(2):349-55
pubmed: 25598015
Clin Cancer Res. 2013 Jan 15;19(2):450-61
pubmed: 23209032
Oncol Lett. 2019 Mar;17(3):3517-3522
pubmed: 30867792